> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Arrowhead Revenue Falls To $450.8 Million From $829.4 Million As REDEMPLO Prescriptions Grow
- URL: https://www.bullished.co/arrowhead-revenue-falls-to-450-8-million-from-829-4-million-as-redemplo-prescriptions-grow-9c8e22d6/
- Published: 2026-11-12T22:40:44.000Z
- Updated: 2026-11-12T22:40:44.000Z
- Description: Annual costs included a $215 million review voucher that Arrowhead retains while pursuing a broader use for REDEMPLO.
- Author: Matteo Parrino
- Tags: SEC Filings, ARWR, Industry: Healthcare

[Arrowhead Pharmaceuticals](https://www.bullished.co/tag/arwr/), which sells the triglyceride-lowering medicine REDEMPLO, reported annual revenue of [$450.8 million](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000077/arwr-20261112.htm?ref=bullished.co), down from $829.4 million in 2025, in results accompanying Thursday's SEC filing. New prescriptions rose 63% from the previous quarter, but the annual loss attributable to Arrowhead widened to $724.2 million from $1.6 million.

## A $215 Million Review Voucher

Arrowhead lost $5.11 per diluted share in the fiscal year ended September 30, compared with $0.01 a year earlier. Research and development costs increased to $739.1 million from $607.2 million, and selling and administrative spending reached $202 million, up from $123.9 million.

The company also spent [$215 million](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000077/arwr-202611128kex991.htm?ref=bullished.co) buying an FDA priority-review voucher, which can accelerate an application review. Total operating expenses rose to $1.2 billion from $731.1 million, and Arrowhead recorded a $707.2 million operating loss against a $98.3 million operating profit in 2025.

Arrowhead retains the voucher because its application for a broader REDEMPLO indication qualified for the FDA's separate Split Real Time Application Review pilot program. That program provides a six-month priority review instead of the standard 10 months, with an earlier decision possible.

Year-end cash, restricted cash and investment securities totaled $1.2 billion, compared with $919.4 million a year earlier.

## REDEMPLO's Growing Prescriber Base

REDEMPLO prescriptions totaled 950 cumulatively at quarter-end, with another 300 received afterward. Weekly prescriptions reached approximately 50–60, and prescribing practitioners increased from more than 640 at quarter-end to over 860 afterward. U.S. insurance formularies now cover 160 million people.

“We are building a [commercial business around](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000077/arwr-202611128kex991.htm?ref=bullished.co) REDEMPLO,” said Christopher Anzalone, Arrowhead's president and CEO.

The medicine uses RNA interference to silence a gene responsible for producing a protein that slows triglyceride clearance. Patients administer it as an injection every three months. Its approved U.S. use is alongside dietary changes for adults with familial chylomicronemia syndrome, a rare disease associated with elevated triglycerides.

European Commission authorization in June 2026 paved the way for [availability in Germany](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000077/arwr-202611128kex991.htm?ref=bullished.co), where the medicine is being prescribed, dispensed and reimbursed. U.K. regulators also authorized it, and funding guidance supports NHS use in England and Wales for adults with genetically confirmed disease whose response to diet and conventional treatments has been inadequate.

## A Broader Launch And Easier Debt Terms

Arrowhead submitted an FDA application to expand REDEMPLO's use to patients with severely elevated triglycerides. It is preparing for a potential U.S. launch in the second quarter of 2027, pending regulatory review and approval, and plans applications elsewhere.

Two late-stage studies met their main triglyceride-reduction goals and all prespecified secondary goals. Median triglyceride reductions from baseline were [79% and 81%](https://www.businesswire.com/news/home/20261112186323/en/Arrowhead-Pharmaceuticals-Reports-2026-Fiscal-Year-End-Results?ref=bullished.co). Arrowhead also expects its fully enrolled late-stage zodasiran trial for a rare inherited condition causing severely elevated cholesterol to finish in mid-2027.

Arrowhead completed a [new $400 million](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000063/arwr-202611048kex991.htm?ref=bullished.co) term loan with funds managed by Sixth Street on Wednesday of last week. The refinancing removed required repayments linked to certain commercial revenue and partnership proceeds and extended maturity to November 2031.

The new loan charges the secured overnight financing rate plus 5.50%, compared with a 15% annual rate on the retired facility. Arrowhead negotiated a $68 million discount on the old loan's contractual prepayment amount.

The board approved a December 31 financial year-end on Monday, effective January 1, 2027\. Arrowhead expects a transition report covering October through December 2026.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — ARROWHEAD PHARMACEUTICALS, INC. (ARWR)](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000077/arwr-20261112.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit arwr-202611128kex991.htm — ARROWHEAD PHARMACEUTICALS, INC. 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000077/arwr-202611128kex991.htm?ref=bullished.co) — SEC EDGAR
- [Arrowhead Pharmaceuticals Reports 2026 Fiscal Year-End Results](https://www.businesswire.com/news/home/20261112186323/en/Arrowhead-Pharmaceuticals-Reports-2026-Fiscal-Year-End-Results?ref=bullished.co) — businesswire.com
- [8-K filed 2026-11-04 — ARROWHEAD PHARMACEUTICALS, INC. (earlier disclosure)](https://www.sec.gov/Archives/edgar/data/0000879407/000087940726000063/arwr-202611048kex991.htm?ref=bullished.co) — SEC EDGAR

### More on Arrowhead Pharmaceuticals

- [Arrowhead Retires 15% Sixth Street Debt At A $68 Million Discount, Takes SOFR-Plus Loan](https://www.bullished.co/arrowhead-retires-15-sixth-street-debt-at-a-68-million-discount-takes-sofr-plus-loan-1eba49b8/)

[All Arrowhead Pharmaceuticals (ARWR) coverage →](https://www.bullished.co/tag/arwr/)